Studiendaten

Bempikibart for Severe Alopecia Areata: A New Hope for Hair Regrowth

by

Q32 Bio Inc. is scheduled to release top-line results from its Phase 2 SIGNAL-AD clinical trial today at 2:00 p.m. ET. The study evaluates the efficacy and safety of bempikibart, a monoclonal antibody designed to treat moderate-to-severe alopecia areata, an autoimmune condition characterized by patchy hair loss. Investors and the medical community are monitoring these … Read more

Breaking Cancer Research: How a Bavarian Foundation Doubles Funding for Revolutionary Oncology Innovations – A Game-Changer in the Fight Against Cancer

by

Breakthrough in Immunotherapy: Walter Schulz Foundation Honors Research into CAR-T Cell Complications In a significant recognition of medical innovation, the Walter Schulz Foundation in Bad Wörishofen has awarded its 2024 Research Prize to a scientist uncovering critical nuances in the field of cancer immunotherapy. The award highlights a pivotal discovery regarding the long-term complications associated … Read more